Middle East and Africa Gastric Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Confirmatory Test, Gastric Cancer Screening Tests/Physical Exam), Age Group (Adult, Pediatric, and Geriatrics), Disease Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales) - Industry Trends and Forecast to 2030.
中东和非洲胃癌诊断市场分析和观察
中东和非洲老年病人口的增加正在推动胃癌诊断业的发展。 胃肠道肿瘤和淋巴瘤的流行也助长了胃癌诊断的需求. 关键的市场制约因素是需要降低癌症诊断检测的高价格,以便即使是发展中国家也能从中受益。
大量市场参与者正在提供胃癌诊断产品,创新为中东和非洲胃癌诊断市场的增长铺平道路。
数据桥市场研究分析认为,预计到2030年,中东和非洲胃癌诊断市场将达到6,963万美元,预测期间为7.4%。 试剂和消耗品在市场上占了最大的产品类型部分,因为对药包和试剂的需求不断增加,而卫生支出的增加也加速了对智能医疗器械的需求.
|
报表计量 |
细节 |
|
预测期 |
2023年至2030年统计 |
|
基准年 |
2022 |
|
历史年代 |
2021 (2015-2020年可控) |
|
数量单位 |
单位:单位:单位,定价 |
|
覆盖部分 |
按产品类型(仪器、试剂和消耗品、服务)、诊断类型(诊断测试、胃癌检查测试/体检)、年龄组(Adult、小儿科和老年科)、疾病类型(Adenocarcinoma、Carcoid Tumor、胃肠胃分泌肿瘤(GIST)、胃淋巴等)、阶段(第0阶段、第一阶段、第二阶段、第三阶段)、性别(男、女)、样本类型(Blood、Tissue、Urine和Stool)、终端用户(诊断实验室、医院、癌症研究所、肿瘤专科诊所等)、分发渠道(分解和零售销售) |
|
涵盖国家 |
沙特阿拉伯、南非、美国、以色列、埃及以及中东和非洲其他地区 |
|
覆盖的市场玩家 |
BIOMÉRIEUX、Myriad遗传学公司、Vela诊断学公司、Abbott、Thermo Fisher科学公司、F. Hoffmann-La Roche有限公司、通用电气、Agilent技术公司、Biohit Oyj、DiaSorin S.p.A、Paragon基因组学公司和QIAGEN等 |
市场定义
胃癌是一类始于胃部并蔓延到全身的癌症. 胃是位于腹部上部肋骨下方的肌肉口袋. 胃取入并持有我们所吃的食物后再分解并消化. 胃癌,通称胃癌,可以发于胃中的任何部分. 胃癌在世界上大部分地区的主要胃部(骨骼)会发作. 用于诊断癌症的各种诊断测试包括预筛测试,活检,生物标记,成像测试,PET/CT扫描等,以及超声波等.
癌症由无控制,异常的细胞扩散所引起,细胞扩散具有扩散和侵入身体其他部分的能力. 基因的变化导致单个细胞或少数细胞扩张和复制,这就是癌症开始的时候. 这可能导致肿瘤的生长,而肿瘤是组织异常的质量. 胃膜中癌细胞的产生被称为胃癌或胃癌. 饮食和胃病既是胃癌的风险因素.
中东和非洲胃癌诊断市场动态
本节讨论了解市场驱动力、优势、机会、制约因素和挑战。 下文详细讨论所有这些问题:
司机
- 胃肠道肿瘤、淋巴瘤和腺癌发病率增加
根据在"临床医学"上发表的一份报告,胃癌是2020年全球第五大常见癌症和第四大癌症死因. 2020年,全世界估计诊断出110万起胃癌病例(720 000名男性和370 000名女性)。 每12起肿瘤死亡中有1起死于胃癌。 每年,世界各地约有一百万起新的胃癌病例被诊断出。
预计,由于人口老化和不断增加、生活方式和社会经济变化,胃癌发病率将上升。 癌症在全球不同地区的负担和分布反映了种族、社会文化规范、行为和饮食趋势的显著变化。
因此,预计全球癌症发病率的上升会加快胃癌诊断的需求。 因此,胃肠道肿瘤、淋巴瘤和腺癌发病率的上升预计将推动中东和非洲胃癌诊断市场的增长。
- 酗酒和吸烟激增
流行病学,临床和实验室的证据表明了吸烟和酗酒之间的行为关系. 香烟和酒精的混合使用除了引起吸烟引起的健康问题外,还引起健康问题,因此是一个需要进一步研究的严重公共卫生问题。
每次吸烟者吸入一盏点燃的香烟,产生数十种危险化学品,都会发生化学链反应. 烟雾含有通过口舌吸入口腔、喉咙和肺部的物质,产生炎症并使这些身体部位接触致癌化学品。
因此,酒精消费和吸烟激增预计将推动中东和非洲胃癌市场的增长。
机会
-
采用自动化系统
癌症是一种系统和网络疾病。 这表明在癌细胞中,某些与网络相关的基因停止正常工作. 应在癌症治疗中处理这些基因网络中复杂的相互作用。人工智能(AI)算法尤其已经迅速发展,这反映在肿瘤学的进步上.
机器学习和神经网络在精密肿瘤学和系统医学方面正变得越来越重要. 将成像数据与临床和分子数据结合起来,开创了一个充满可能性的世界. 例如,无线电基因组学是一个侧重于多维数据处理的新领域。 它还可以从AI进步中受益.
因此,日益采用自动化系统是这一市场增长的一个机会。
限制/挑战
- 健康保险政策缺乏足够的财政支持
为了实现其目标,卫生系统需要财政资源。 人力资源、医院护理和药物是大多数保健系统中最昂贵的方面。 在大多数热带国家,保健资金由政府、私人(主要是自付)支出和国际援助相结合提供。
保健筹资仍然是中低收入国家的主要关切。 拉丁美洲、非洲和亚洲的许多中上收入国家都能够建立覆盖其大部分人口的保健筹资安排。 这些措施使人们能够获得保健服务,同时保护个人免于因获得保健服务而承受的灾难性债务。 另一方面,财政是低收入国家(大部分在撒哈拉以南非洲)提供保健服务的主要障碍。
因此,健康保险政策缺乏足够的财政支持,限制了市场的增长。
最近的事态发展
- 2022年10月,通用电气公司与剑桥大学医院,索菲亚遗传学等多所研究机构合作,更早与奥普特勒姆合作,与人工智能合作使用成像数据. 这将有助于缩短几种癌症的诊断时间,并帮助为患者提供个性化护理. 这帮助公司拓宽了癌症诊断的视野
- 2020年3月,Thermo Fisher科学公司宣布将收购以Netherland为基地的分子诊断和保健公司QIAGEN. 该公司的这一收购将增加其在市场上的产品组合,导致今后收入增加
中东和非洲胃癌诊断市场范围
中东和非洲胃癌诊断市场按产品类型、诊断类型、年龄组、疾病类型、舞台、性别、样本、最终用户和分销渠道分为9个值得注意的部分。 不同部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域以及目标市场的差异。
产品类型
- 文书
- 试剂和消耗品
- 服务
根据产品类型,市场被分割成仪器,试剂和消耗品,以及服务.
数字类型
- 确认试验
- 胃癌筛查测试/体检
根据诊断类型,市场分为胃癌筛查检测/物理检测和确认检测.
年龄组
- 成人
- 儿科
- 老年病
根据年龄组,市场分为成人、儿科和老年科。
类型
- 肠道或肠道
- 癌肿瘤
- 胃肠胃肿瘤(GIST)
- 胃性淋巴瘤
- 其他人员
根据类型,市场被分化为肠道或分泌性腺癌,卡克诺克瘤,胃肠分泌性腺瘤(GIST),胃淋巴瘤等.
阶段
- 第0阶段
- 第一阶段
- 第二阶段
- 第三阶段
在阶段的基础上,将市场分入了阶段0,阶段一,阶段二,阶段三.
性别
- 男性
- 妇女
按性别,市场分为男性和女性。
模拟类型
- 血迹
- 组织
- 尿液
- 凳子
根据样本类型,市场被分入血液,组织,尿液和凳子.
终止使用
- 诊断实验室
- 医院
- 癌症研究所
- 肿瘤专科诊所
- 其他人员
以终端用户为基础,将市场分为诊断实验室,医院,癌症研究机构,肿瘤专科诊所等.
分配办法
- 直接招标
- 零售
以发售渠道为基础,将市场分入直接招标和零售.
中东和非洲胃癌诊断市场分析/观察
中东和非洲胃癌诊断市场按产品类型、诊断类型、年龄组、疾病类型、舞台、性别、样本、最终用户和分销渠道分为9个值得注意的部分。
本市场报告涵盖的国家有:南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东其他地区和非洲。
2023年,由于对高效和反应灵敏的保健通信的需求增加,南非预计将占据主导地位。
报告的国家部分还介绍了影响市场的因素和国内市场监管的变化,这些变化影响到市场目前和未来的趋势。 诸如新的销售、替代销售、国家人口统计、监管法和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。 此外,在提供国家数据的预测分析的同时,还考虑了中东和非洲品牌的存在和可得性,以及它们由于来自当地和国内品牌的大规模或稀缺竞争而面临的挑战,以及销售渠道的影响。
竞争性景观和胃癌诊断市场份额分析
中东和非洲胃癌诊断市场竞争环境提供了竞争对手提供的细节。 详细内容有:公司概况,公司财务,创收,市场潜力,研发投资,新市场举措,生产场所和设施,公司优势和弱点,产品推出,产品审批,产品宽度和宽度,应用优势,产品类生命线曲线等. 上述数据点仅与公司关注胃癌诊断市场有关.
在中东和非洲经营胃癌诊断市场的一些主要角色有:BIOMÉRIEUX、Myriad基因公司、Vela诊断公司、Abbott、Thermo Fisher科学公司、F.Hoffmann-La Roche有限公司、通用电气、Agilent技术公司、Biohit Oyj、DiaSorin S.p.A、Paragon基因组公司和QIAGEN等。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.4 BRAND ANALYSIS
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
4.6 INDUSTRY INSIGHTS:
5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
6.1.3 INCREASE IN THE GERIATRIC POPULATION
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES
6.3 OPPORTUNITIES
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES
6.4.2 LIMITATIONS OF RADIATION TESTS
7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.2.1 KITS
7.2.1.1 DNA POLYMERASE KITS
7.2.1.2 PCR KITS
7.2.1.3 NUCLEIC ACID ISOLATION KITS
7.2.1.4 OTHERS
7.2.2 REAGENTS
7.2.2.1 ASSAYS
7.2.2.2 BUFFERS
7.2.2.3 PRIMERS
7.2.2.4 OTHERS
7.3 INSTRUMENTS
7.4 SERVICES
8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
8.1 OVERVIEW
8.2 CONFIRMATORY TEST
8.2.1 IMAGING TESTS
8.2.1.1 PET SCAN/CT SCAN
8.2.1.2 CT SCAN
8.2.1.3 ULTRASOUND
8.2.1.4 MRI
8.2.1.5 X-RAY
8.2.2 BIOMARKER
8.2.2.1 DNA BIOMARKER
8.2.2.2 RNA BIOMARKER
8.2.2.3 PROTEIN BIOMARKER
8.2.3 BIOPSY
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM
9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 GERIATRICS
9.3 ADULT
9.4 PEDIATRIC
10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA
10.3 CARCINOID TUMOR
10.4 GASTROINTESTINAL STROMAL TUMOR
10.5 GASTRIC LYMPHOMA
10.6 OTHERS
11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE
11.1 OVERVIEW
11.2 STAGE I
11.2.1 STAGE IA
11.2.2 STAGE IB
11.3 STAGE II
11.3.1 STAGE IIA
11.3.2 STAGE IIB
11.4 STAGE III
11.4.1 STAGE IIIA
11.4.2 STAGE IIIB
11.4.3 STAGE IIIC
11.5 STAGE 0
12 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
13.1 OVERVIEW
13.2 STOOL
13.3 TISSUE
13.4 BLOOD
13.5 URINE
14 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC LABORATORIES
14.4 CANCER RESEARCH INSTITUTES
14.5 ONCOLOGY SPECIALTY CLINICS
14.6 OTHERS
15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 U.A.E
16.1.4 EGYPT
16.1.5 ISRAEL
16.1.6 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GENERAL ELECTRIC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 ABBOTT
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 QIAGEN
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 MYRIAD GENETICS, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACON LABORATORIES, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ADVACARE PHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AGILENT TECHNOLOGIES, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BIOMÉRIEUX
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BIOCEPT, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 BIOHIT OYJ
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DIASORIN S.P.A
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 ENDOFOTONICS PTE LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 FOUNDATION MEDICINE, INC.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 FUJIREBIO (AN H.U. GROUP COMPANY)
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 MIRXES PTE LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 PARAGON GENOMICS, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TECO DIAGNOSTICS
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 VELA DIAGNOSTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE
TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-
TABLE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 70 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 SOUTH AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 SOUTH AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 SOUTH AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 75 SOUTH AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 76 SOUTH AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 77 SOUTH AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 78 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 SAUDI ARABIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 106 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 U.A.E REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 U.A.E KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 U.A.E REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 110 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 111 U.A.E CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.A.E IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.A.E BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 114 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 115 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 117 U.A.E STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 118 U.A.E STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 120 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 121 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 122 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 123 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 124 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 EGYPT REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 EGYPT KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 EGYPT REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 129 EGYPT CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 130 EGYPT IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 131 EGYPT BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 132 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 133 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 134 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 136 EGYPT STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 137 EGYPT STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 138 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 139 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 140 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 141 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 142 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 ISRAEL REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 ISRAEL KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 ISRAEL REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 146 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 147 ISRAEL CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 148 ISRAEL IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 149 ISRAEL BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 150 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 151 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 152 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 153 ISRAEL STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 160 REST OF MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID
FIGURE 11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
FIGURE 15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022
FIGURE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 22 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 24 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022
FIGURE 28 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022
FIGURE 32 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 36 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022
FIGURE 40 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 44 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 52 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 53 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
